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Abstract
Background: The Ras-dependent ERK1/2 MAP kinase signaling pathway plays a central role in cell proliferation control
and is frequently activated in human colorectal cancer. Small-molecule inhibitors of MEK1/MEK2 are therefore viewed
as attractive drug candidates for the targeted therapy of this malignancy. However, the exact contribution of MEK1 and
MEK2 to the pathogenesis of colorectal cancer remains to be established.
Methods: Wild type and constitutively active forms of MEK1 and MEK2 were ectopically expressed by retroviral gene
transfer in the normal intestinal epithelial cell line IEC-6. We studied the impact of MEK1 and MEK2 activation on cellular
morphology, cell proliferation, survival, migration, invasiveness, and tumorigenesis in mice. RNA interference was used
to test the requirement for MEK1 and MEK2 function in maintaining the proliferation of human colorectal cancer cells.
Results: We found that expression of activated MEK1 or MEK2 is sufficient to morphologically transform intestinal
epithelial cells, dysregulate cell proliferation and induce the formation of high-grade adenocarcinomas after orthotopic
transplantation in mice. A large proportion of these intestinal tumors metastasize to the liver and lung. Mechanistically,
activation of MEK1 or MEK2 up-regulates the expression of matrix metalloproteinases, promotes invasiveness and
protects cells from undergoing anoikis. Importantly, we show that silencing of MEK2 expression completely suppresses
the proliferation of human colon carcinoma cell lines, whereas inactivation of MEK1 has a much weaker effect.
Conclusion: MEK1 and MEK2 isoforms have similar transforming properties and are able to induce the formation of
metastatic intestinal tumors in mice. Our results suggest that MEK2 plays a more important role than MEK1 in sustaining
the proliferation of human colorectal cancer cells.
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Background
Colorectal cancer arises from intestinal epithelial cells in
a multistep process that extend over several years and
leads to the progression from a normal mucosa to aber-
rant crypt foci to benign adenomas up to invasive carcino-
mas [1]. Histo-pathological progression of colorectal
tumors is associated with the progressive accumulation of
genetic alterations in tumor suppressor genes and onco-
genes [2]. The most frequently mutated oncogene in
colorectal tumors is KRAS, a member of the RAS gene fam-
ily. Activating mutations in the three RAS genes, most fre-
quently in KRAS, have been found in ~30% of human
neoplasias and are often an early event in tumor progres-
sion [3]. Specifically, KRAS  mutations are detected in
approximately 35% of all sporadic colorectal adenomas
and carcinomas [3,4]. Genetic and biochemical studies
have firmly established the central role of Ras GTPases in
regulating cell proliferation, growth and survival [5,6].
More than ten distinct classes of Ras effectors have been
identified to date, several of which are associated with
oncogenic signaling pathways [7]. The best-characterized
of the Ras effector pathways is the activation of the Raf
family Ser/Thr kinases, leading to sequential phosphor-
ylation and activation of MEK1/MEK2 and the mitogen-
activated protein (MAP) kinases ERK1/ERK2 [8]. The
importance of Raf in oncogenic signaling has been vali-
dated by the discovery of activating BRAF mutations in a
variety of human tumors [9], including 14% of colorectal
cancers [3].
Raf relays its oncogenic signals mainly via the MAP kinase
kinases MEK1 and MEK2. Early studies have shown that
expression of activated alleles of MEK1 is sufficient to
deregulate the proliferation and trigger the morphological
transformation of immortalized fibroblast [10,11] and
epithelial [12-14] cell lines. In vivo, orthotopic transplan-
tation of mammary epithelial cells expressing activated
MEK1 into syngeneic mice rapidly produced invasive ade-
nocarcinomas [13]. Transgenic expression of active MEK1
in mouse skin induced hyperplasia, hyperkeratosis and
perturbed differentiation of the epidermis [15,16]. Con-
versely, treatment with MEK1/2 inhibitors was shown to
inhibit the proliferation of various carcinoma and leuke-
mic cell lines [17,18]. Notably, administration of an
orally-available inhibitor of MEK1/2 elicited marked anti-
tumor efficacy in mouse xenograft models of colon cancer
and metastatic melanoma [19,20]. In parallel, several
studies using clinical specimens have documented the up-
regulation and/or activation of MEK1/MEK2 and the MAP
kinases ERK1/ERK2 in solid tumors and leukemias (see
[21] and references therein). Collectively, these findings
have provided strong rationale for the development of
small-molecule inhibitors of MEK1/2 for chemotherapeu-
tic intervention in cancer.
MEK1 and MEK2 display 85% amino acid identity overall
and are expressed ubiquitously in cell lines and tissues.
Although it is commonly assumed that the two isoforms
are functionally equivalent, several lines of evidence,
however, indicate that they are regulated differentially
and may exert non-redundant functions [22-24]. Studies
using RNA interference have suggested that both MEK1
and MEK2 are required for in vitro cell proliferation, and
that they contribute to distinct cell cycle regulatory events
[25]. However, the individual roles of MEK1 and MEK2 in
tumorigenesis remain to be explored. Intriguingly, a
recent report has shown that activated MEK1 but not
MEK2 can promote epidermal hyperplasia in transgenic
mice, even though both MEK proteins trigger ERK1/ERK2
phosphorylation [16].
Colorectal cancers often display activation of the ERK1/2
MAP kinase pathway and therefore represent potential tar-
gets for MEK1/2 inhibitors [26]. In this study, we have
evaluated the ability of the two MEK isoforms to trans-
form intestinal epithelial cells and to promote tumor for-
mation and progression in vivo. Our results demonstrate
that activation of either MEK1 or MEK2 is sufficient for
full transformation of intestinal epithelial cells up to the
invasive stage. Importantly, we show that MEK2 expres-
sion is essential for the proliferation of human colon can-
cer cells.
Methods
Cell culture and infections
IEC-6 is a rat epithelial cell line with features of undiffer-
entiated small intestinal crypt cells [27]. HCT116 [28],
HT-29 [29] and SW480 [30] are human colorectal adeno-
carcinoma cell lines. MDA-MB-231 is a human breast ade-
nocarcinoma cell line [31]. IEC-6, HCT116, HT-29 and
MDA-MB-231 cells were cultured in DMEM containing
10% fetal bovine serum, 2 mM glutamine and antibiotics.
SW480 cells were cultured in RPMI supplemented with
10% fetal bovine serum. IEC-6 cells were infected with ret-
roviral vectors as previously described [32]. Populations
of infected cells were selected with 4 μg/ml puromycine.
Mouse in vivo tumor studies
All animals were housed under pathogen-free conditions,
and experiments were performed in accordance with
CCAC guidelines and with Université de Montréal Institu-
tional Animal Care and Use Committee approval. Female
Balb/c athymic nude mice (nu/nu) were purchased from
Harlan and used at 6–8 weeks of age. For subcutaneous
tumor model studies, IEC-6 cells were harvested from sub-
confluent cultures by brief exposure to 0.25% trypsin and
0.02% EDTA. The cells were washed once in PBS, and 3 ×
104 cells in a final volume of 200 μl were injected subcu-
taneously in the flanks of the mouse. The mice were mon-BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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itored regularly and the tumors were measured every 2–3
days using a caliper.
For orthotopic tumor model studies, 1 × 105 IEC-6 cells in
a volume of 30 μl were implanted in the ceacum of nude
mice. Mice were anaesthetized with isoflurane during the
surgical procedure. The caecum was exteriorized through
a small midline laparotomy and cells were injected in the
cecal wall. After implantation, the abdominal wall was
closed and sutured, and the mice received a subcutaneous
injection of 0.05 mg/kg buprenorphin for postoperative
pain relief. The mice were monitored regularly and sacri-
ficed when they became moribund or manifested signs of
disease. Following necropsy, the caecum, lungs and liver
were excised, fixed in formalin and embedded in paraffin.
Serial sections of the intestine and of lung and liver (0.3
mm apart) tissues were prepared and stained by H&E for
histopathological evaluation.
Plasmids and antibodies
Human HA-tagged MEK1 and MEK2 cDNA constructs
were used as templates for in vitro mutagenesis to generate
the constitutively activated MEK1(S218D/S222D)
(MEK1DD) and MEK2(S222D/S226D) (MEK2DD)
mutants as previously reported [33]. All mutations were
confirmed by DNA sequencing. All MEK constructs were
subcloned into pBabe-puro vector for infection of IEC-6
cells.
Commercial antibodies were from the following sources:
Bcl-2, Mcl-1 and GAPDH (FL-335) antibodies from Santa-
Cruz Biotechnology; smooth muscle α-actin (clone 1A4),
total actin (clone AC40) and α-tubulin (clone DM1A)
from Sigma ; MEK1 (clone 25), MEK2 (clone 96),
fibronectin (Clone 10) and E-cadherin (clone 36 for
immunofluorescence and clone 34 for immunoblotting)
from Transduction Laboratories; pan-cytokeratin (clone
B311.1) and MMP-13 from Calbiochem ; vimentin from
Chemicon (for immunofluorescence) and NeoMarkers
(Ab-2; for immunoblotting); phospho-MEK1/2, Bcl-xL
and Bim from Cell Signaling Technology.
Immunoblotting, protein kinase assays and 
immunofluorescence analysis
Cell lysis, immunoprecipitation and immunoblot analy-
sis were performed as described previously [34]. The
phosphotransferase activity of ectopically expressed
MEK1 and MEK2 was assayed by measuring their ability to
increase the myelin basic protein kinase activity of recom-
binant ERK2 in vitro as previously described [35].
Immunofluorescence staining was performed as described
[36]. Cell samples were viewed by fluorescence micros-
copy on a Leica DM IRB microscope.
Real-time quantitative PCR analysis
Total RNA was isolated using the RNeasy Mini Kit (Qia-
gen) and was reversed transcribed and amplified using
primers-probe set from Exiqon Universal ProbeLibrary.
Real-time analysis of PCR product amplification was per-
formed on the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems). The mouse ribosomal 18S
gene was used as endogenous control. The relative level of
target gene expression was quantified using the ΔΔCT
method.
Cell proliferation and transformation assays
Cell proliferation in vitro was measured by the colorimet-
ric MTT assay. Briefly, exponentially growing cells were
cultured in 24-well plates in complete DMEM medium.
Cell proliferation was determined at 24 h intervals by
replacing the culture medium with 0.05 ml of MTT solu-
tion (1 mg/ml MTT). The cells were then incubated at
37°C for 1 h prior to addition of 100 μl of the solubilizer
solution (DMSO with 2% (v/v) of glycine 0.1 M, pH 11).
The absorbance was determined at 550 nm with reference
at 620 nm.
Anchorage independence growth was evaluated as origi-
nally described [37]. Briefly, cells (2.5 × 104) were resus-
pended in 2 ml of top agar (0.4% Noble agar (Difco) in
DMEM, 10% calf serum, 2 mM glutamine, and antibiot-
ics) and overlaid on a solid layer of 5 ml of 0.7% agar in
the same medium in 60-mm tissue culture plates. The
cells were fed weekly with 1 ml of top agar in complete
medium. The plates were examined for the presence of
colonies after 21 days.
Migration and invasion assays
Cell migration and invasion were determined using a
modified two-chamber migration assay. Membranes (8-
μm pore size; Neuro Probe) were either coated with 50
mg/ml collagen type I (migration assays) or with a layer of
Matrigel extracellular matrix proteins (BD Bioscience) for
invasion assays. The cells (5.5 × 104) were seeded in
serum-free medium in the upper chamber and allowed to
migrate to the lower chamber containing 10% fetal
bovine serum as chemoattractant. After 6 h, the cells in the
upper chamber were carefully removed using a wiper
blade and the cells on the bottom side of the membrane
were fixed and stained with Diff-Quick Stain Set (Fisher).
The stained membrane was then digitally scanned and the
density of cells was quantified using the NIH Image soft-
ware. Essentially similar results were obtained when the
stained cells were counted manually.
Detachment-induced apoptosis assay
Tissue culture plates were coated twice with 5 mg/ml Poly-
HEMA (Sigma), allowed to dry at room temperature and
rinsed with PBS. IEC-6 cells were added to the coatedBMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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plates in complete growth medium at a density of 4 × 104
cells/cm2 for the indicated times. The cells were then har-
vested, rinsed with PBS and counted. Apoptosis was meas-
ured on an aliquot of 104 cells using a cell death detection
ELISA kit (Roche Diagnostics) according to the manufac-
turer's procedure.
Gelatin and casein zymography assays of MMPs
Conditioned medium harvested from IEC-6 cells was
mixed with 2× Laemmli's sample buffer and incubated on
ice for 10 min. The samples were analyzed by electro-
phoresis on a 10% SDS-acrylamide gel containing 1 mg/
ml gelatin (Sigma) or on a Novex 12% Zymogram
(casein) Gel (Invitrogen). The gel was washed twice in
2.5% Triton X-100 for 30 min to remove all traces of SDS,
and then incubated overnight at 37°C in 50 mM Tris-HCl
(pH 7.6), 10 mM CaCl2, 100 mM NaCl and 0.05% Brij35.
Then, the gel was stained with 0.05% Coomassie,
destained and dried.
shRNA lentiviral infections
The shRNA constructs for human MEK1 (MAP2K1) and
MEK2 (MAP2K2) genes were purchased from Open Bio-
systems. These constructs from The RNAi Consortium
(TRC) library consist of 21 base stem and 6 base loop hair-
pins cloned in pLKO1 lentiviral vector. The HIV packaging
(pMDLg/p REE and pRSV-REV) and VSV-G (pMD2-VSVG)
plasmids were kindly provided by D. Trono (École Poly-
technique Fédérale de Lausanne). For lentivirus produc-
tion, 2 × 106 293T cells were cultured overnight in T25
flasks and co-transfected with 6 μg of plasmid vector, 1.5
μg of pMDLg/p REE, 3 μg of pMD2-VSVG and 1.5 μg of
pRSV-REV using the calcium phosphate precipitation
method. Viral supernatants were collected after 42 h. For
infection of human carcinoma cell lines, cells were plated
at a density of 1–4.5 × 106 cells per 10-cm Petri dish the
day before, and were then incubated with viral superna-
tant in the presence of 4 μg/ml polybrene for 5 h. After
infection, the cells were washed twice with PBS, and cul-
tured for 72 h before harvesting. The yield of infection was
estimated by parallel infection of the cells with a GFP-
encoding lentiviral vector. A similar efficiency of transduc-
tion was obtained in the colorectal and breast cancer cell
lines used in this study.
Affymetrix GeneChip analysis
Total RNA was isolated from empty vector-, MEK1DD-,
and MEK2DD-expressing IEC-6 cells (duplicate samples)
using RNeasy RNA isolation kit (Qiagen). The quality of
the RNA was assessed by determining the 260/280 nm
absorbance ratios and by gel electrophoresis in agarose/
formaldehyde gels. Reverse transcription, second-strand
synthesis, and cRNA labeling were all performed using
standard Affymetrix protocols. Biotinylated cRNAs were
hybridized to rat Genome U34A GeneChips (Affymetrix)
on an Affymetrix Fluidics Station at the McGill Genome
Centre. After scanning of the gene chips, images were ana-
lyzed and the expression values were normalized using
the Affymetrix Microarray Analysis Suite (v5.0). The
resulting expression values were analyzed using empirical
Bayes methodology [38].
Results
Constitutive activation of MEK1 or MEK2 is sufficient for 
transformation of intestinal epithelial cells and formation 
of tumors in vivo
Immunohistochemistry analysis of a colorectal cancer tis-
sue microarray containing over 400 colorectal cancer and
50 normal colon tissue biopsies revealed that 44% of
colorectal cancers display high cytoplasmic expression of
phosphorylated MEK1/MEK2 as compared to 10% of nor-
mal tissues (analysis to be published elsewhere). To assess
the functional significance of MEK1/MEK2 activation in
colorectal cancer, we ectopically expressed wild type and
constitutively active (DD mutant) versions of MEK1 and
MEK2 by retroviral gene transfer in the normal undiffer-
entiated intestinal epithelial cell line IEC-6 [27]. Polyclo-
nal populations of infected clones were selected in
puromycin and used for subsequent experiments. Immu-
noblot analysis confirmed that ectopic MEK isoforms are
expressed at comparable levels in IEC-6 transduced popu-
lations (Fig. 1A). Overexpression of wild type MEK1 or
MEK2 did not affect the expression of endogenous MEK
isoforms. However, ectopic expression or MEK2DD
slightly increased the steady-state levels of endogenous
MEK1, while overexpression of MEK1DD had a similar
effect on MEK2 levels (Fig. 1B). As expected, substitution
of the activation loop Ser phosphorylation sites by Asp
residues strongly potentiated the enzymatic activity of
MEK1 and MEK2, but no reproducible difference in activ-
ity was observed between the two isoforms (Fig. 1C).
IEC-6 cells grow as a monolayer and display a typical epi-
thelial morphology with organized cell-cell adhesions
(Fig. 1D). Overexpression of wild type MEK isoforms had
no noticeable effect on the morphology of IEC-6 cells. In
contrast, expression of activated MEK1 or MEK2 led to
drastic morphological changes accompanied by loss of
cell-cell contacts; the cells adopted a spindle-like fibrob-
last morphology, were more refractile and formed multi-
layers. These changes are characteristic of epithelial-
mesenchymal transitions (EMT) that play an important
role in tumor progression [39]. To determine whether
MEK1DD- and MEK2DD-expressing cells undergo an
EMT, we examined the localization and measured the
expression levels of various epithelial and mesenchymal
markers. Parental and vector-infected IEC-6 cells showed
a polarized basolateral membrane distribution of the epi-
thelial marker E-cadherin, with basal expression of the
fibroblast marker vimentin (Fig. 1E). Ectopic expressionBMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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of MEK1DD or MEK2DD resulted in the loss of E-cad-
herin staining at the plasma membrane (Fig. 1E), con-
comitant with a marked reduction of E-cadherin protein
and mRNA levels (Fig. 1F and 1G). No significant change
in the expression of keratins and no induction of the mes-
enchymal proteins vimentin and smooth muscle α-actin
(we instead observed a decreased expression) were
observed in these cells (Fig. 1F). These results indicate that
constitutive activation of MEK1 or MEK2, while disrupt-
ing normal epithelial morphology and polarization, is not
sufficient to induce a full EMT in intestinal epithelial cells.
This epithelial plasticity change has been referred to as
scattering and is distinct from EMT [40].
We examined whether constitutive activation of MEK1 or
MEK2 was conferring some proliferation advantage to
intestinal epithelial cells. Ectopic expression of either acti-
vated MEK1 or MEK2 significantly increased the prolifer-
ation rate of IEC-6 cells grown in 10% serum containing-
medium when compared to vector-infected cells or cells
overexpressing wild type MEK isoforms (Fig. 2A). This
increase in proliferation was not observed in low serum
(2%) containing-medium (data not shown). Both acti-
vated MEK1 and MEK2 conferred anchorage-independ-
ence growth to IEC-6 cells (Fig. 2B). To test the
tumorigenic potential of IEC-6 transduced cell popula-
tions in vivo, the cells were injected subcutaneously into
athymic mice. Cells infected with vector or wild type MEK
isoforms never formed any tumor (Fig. 2C). In contrast,
both MEK1DD- and MEK2DD-expressing cells generated
rapidly growing tumors in all injected mice. Injection of as
low as 3 × 104 cells produced tumors of ~1,000 mm3 after
2 weeks. No major difference was observed in the growth
rate of tumors expressing activated MEK1 or MEK2 (Fig.
2D).
To analyze the impact of active MEK isoforms on tumori-
genesis in a more pathologically relevant model, IEC-6
transduced cells were orthotopically transplanted into the
caecum of athymic mice. This model more closely recapit-
ulates human colorectal cancer progression, in particular
the spontaneous metastatic process that is highly depend-
ent on the host environment [41]. Strikingly, 100% of the
mice transplanted with 105 IEC-6 cells expressing either
MEK1DD or MEK2DD developed massive intestinal
tumors, while the control group remained tumor-free
(Fig. 2C and 2E). The mice were sacrificed when they
became moribund or presented symptoms of weight loss,
respiratory distress, or a palpable abdominal mass. Micro-
scopic examination of the tumors revealed a poorly differ-
entiated morphology with occasional signet-ring cells
(inset) corresponding to a high-grade adenocarcinoma
(Fig. 2E). The tumors are invasive and diffusely infiltrate
the lamina propria and the underlying muscular layers
(muscularis propria and muscularis mucosae). Together,
these data demonstrate that constitutive activation of
MEK1 or MEK2 is sufficient to transform intestinal epithe-
lial cells and induce the formation of invasive colon ade-
nocarcinomas.
Constitutive activation of MEK1 or MEK2 confers 
metastatic properties to transformed intestinal epithelial 
cells
Activation of the ERK1/2 MAP kinase pathway has been
implicated in the regulation of cell motility and invasion
[42]. Notably, treatment of colon carcinoma cells with the
MEK1/2 inhibitor PD184352 was shown to inhibit HGF-
induced cell scattering and to reduce their invasive prop-
erties [20]. We examined the impact of MEK1 or MEK2
activation on the motility of IEC-6 cells using two differ-
ent cell migration assays. No difference in the migration
rate of the different IEC-6 transduced populations was
observed in a standard chemotaxis assay with serum as
chemoattractant (Fig. 3A). Similar results were obtained
using a wound-healing assay (data not shown). We next
analyzed the ability of the cells to migrate through a
Matrigel-coated membrane as a reflection of their invasive
properties. Ectopic expression of activated MEK1 or MEK2
significantly enhanced the invasive capacity of IEC-6 cells,
while the wild type MEK isoforms had no effect (Fig. 3B).
Interestingly, the MEK2DD-transduced cells appeared
Expression of activated MEK1 or MEK2 morphologically transforms intestinal epithelial cells Figure 1 (see previous page)
Expression of activated MEK1 or MEK2 morphologically transforms intestinal epithelial cells. IEC-6 cells were 
infected with retroviruses encoding the indicated MEK constructs and populations of puromycine-resistant cells were selected 
for further analysis. (A) Expression of HA-tagged MEK1 and MEK2 was analyzed by immunoblotting with anti-HA antibody. (B) 
Expression of MEK1 and MEK2 was analyzed by immunoblotting with specific antibodies. (C) The ectopically expressed MEK 
proteins were immunoprecipitated with anti-HA antibody, and phosphotransferase activity was measured using an ERK2 reac-
tivation assay. Results are representative of at least three independent experiments. (D) Morphology of exponentially prolifer-
ating IEC-6 cells stably expressing the indicated MEK constructs was examined by phase-contrast microscopy. (E) 
Immunofluorescence analysis of E-cadherin and vimentin expression. (F) Expression of E-cadherin, cytokeratins, vimentin and 
smooth muscle α-actin was analyzed by immunoblotting in the indicated cell lines. α-Tubulin was used as loading control. (G) 
Quantitative PCR analysis of E-cadherin mRNA levels. Expression levels are expressed as fold-increase relative to vector-
infected cells.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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Figure 2 (see legend on next page)
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more invasive than cells expressing MEK1DD in this
assay.
The invasive properties of the cells in vitro and the histol-
ogy of the intestinal tumors suggest that MEK1DD- and
MEK2DD-expressing IEC-6 cells may have metastatic
properties in vivo. Detailed histological examination of a
subset of mice that develop orthotopic tumors revealed
the presence of metastasis in the lymph nodes, the lungs
and the liver in both the MEK1DD and MEK2DD groups
(Fig. 3C and 3D). These observations indicate that consti-
tutive activation of either MEK1 or MEK2 is sufficient to
confer a metastatic phenotype to intestinal tumor cells.
The acquisition of invasiveness does not result from
changes in cellular motility.
To identify downstream targets of MEK1/MEK2 involved
in intestinal tumor progression, we analyzed the tran-
scriptional profile of MEK1DD- and MEK2DD-expressing
IEC-6 cells using Affymetrix GeneChip arrays. Analysis of
the gene expression data identified several genes that were
up-regulated or down-regulated in MEK1DD- and
MEK2DD-expressing cells as compared to control IEC-6
cells (Additional files 1 and 2). The list of modulated
genes included growth factors, signaling molecules, drug
metabolism enzymes and, interestingly, several proteases.
The matrix metalloproteinases (MMPs) MMP-3 and
MMP-13 were up-regulated in both MEK1DD- and
MEK2DD-expressing cells, while up-regulation of MMP-
10 reached significance only in MEK2DD cells. Expression
of the urokinase receptor was also up-regulated in IEC-6
cells expressing activated MEK2. Because of the impor-
tance of MMPs and urokinase receptor in tumor progres-
sion [43,44], we further validated the regulation of these
genes by MEK1 and MEK2 signaling to confirm the data
from the arrays. No expression or activity of MMPs could
be detected in empty vector-infected IEC-6 cells. However,
activation of either MEK1 or MEK2 markedly up-regulated
the expression of MMP-13 protein (Fig. 4A). Notably,
higher levels of MMP-13 protein were detected in IEC-6
cells expressing the activated MEK2 isoform. The expres-
sion of MMP-3/10 was analyzed by measuring their activ-
ity by zymography in casein-containing gels. Again, we
observed that MEK2DD increased MMP-3/10 enzymatic
activity more robustly than MEK1DD (Fig. 4A). Quantita-
tive PCR analysis confirmed that constitutive activation of
MEK1 or MEK2 induces the expression of urokinase recep-
tor mRNA (Fig. 4B). As observed for the MMPs, the extent
of induction of the urokinase receptor gene was higher in
MEK2DD-expressing cells.
In a previous study, Komatsu et al. [45] have used oligo-
nucleotide microarrays to analyze the gene expression
profile of intestinal epithelial cells expressing a condi-
tional allele of activated MEK1. We have compared the
results of our transcriptional profiling analysis with this
study. Of the 69 gene transcripts that showed altered
expression in the study of Komatsu, 18 (26%) were found
to be modulated in IEC-6 cells expressing constitutively
active MEK1 or MEK2. Importantly, the two studies con-
verge on a series of genes involved in cell proliferation,
cell invasion, tumor suppression and drug metabolism.
Constitutive activation of MEK1 or MEK2 protects 
intestinal epithelial cells against anoikis
Epithelial cancer progression and metastasis is associated
with the acquisition of resistance to anoikis [46]. To fur-
ther explore the mechanism by which MEK1 and MEK2
promote tumor metastasis, we asked whether activated
MEK isoforms protect intestinal epithelial cells from cell
death induced by loss of adhesion. IEC-6-transduced pop-
ulations were placed on poly-HEMA-coated plates in nor-
mal growth medium and the extent of apoptosis was
measured at different times by TUNEL. Detachment from
matrix induced high levels of apoptosis of control IEC-6
cells, which was already detectable at 6 h and increased up
to 24 h (Fig. 5A). Strikingly, expression of either MEK1DD
or MEK2DD almost completely protected IEC-6 cells from
undergoing anoikis.
As a step to understand the molecular mechanism by
which activated MEK isoforms suppress anoikis, we mon-
Expression of activated MEK1 or MEK2 enhances the proliferation of IEC-6 cells and induces the formation of intestinal tumors Figure 2 (see previous page)
Expression of activated MEK1 or MEK2 enhances the proliferation of IEC-6 cells and induces the formation of 
intestinal tumors. (A) IEC-6 cells infected with the indicated constructs were plated in triplicate wells of 24-well plates in 
complete medium containing 10% serum. Cell proliferation was measured each day using the MTT assay. (B) Anchorage-inde-
pendent proliferation was assayed by measuring the formation of cell colonies in soft agar. Results indicate the number of col-
onies after 21 days and are representative of 3 independent experiments. (C) IEC-6 cell populations expressing the indicated 
MEK constructs were either injected subcutaneously (subcutaneous tumors) into the flanks of athymic mice or orthotopically 
transplanted into the cecal wall (cecal tumors) of the mice as described in Methods. The mice were monitored for tumor 
development. (D) Growth rate of subcutaneous tumors. Values represent the average volume +/- SEM of 8 tumors (4 mice). 
Data are representative of 3 independent experiments. (E) Representative pictures of intestinal tumors generated by ortho-
topic implantation of MEK1DD- or MEK2DD-expressing IEC-6 cells in the ceacum. N, normal mucosa; T, tumor. Note the 
poorly differentiated morphology of tumor cells typical of high-grade adenocarcinomas. Inset, signet-ring cells.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
Page 9 of 17
(page number not for citation purposes)
Constitutive activation of MEK1 or MEK2 promotes tumor metastasis to the liver and lung Figure 3
Constitutive activation of MEK1 or MEK2 promotes tumor metastasis to the liver and lung. (A) Motility of IEC-6 
cell populations was assayed by measuring their migration through porous membranes coated with collagen type I in modified 
Boyden chambers. Cells on the bottom side of the membrane were fixed and stained. (B) Invasiveness of IEC-6 cell populations 
was assayed as in A except that membranes were coated with a layer of Matrigel extracellular matrix proteins. Results are 
expressed as fold-increase relative to vector-infected cells. (C) Incidence of metastasis following orthotopic transplantation of 
IEC-6 cell populations in the caecum of mice. (D) Representative pictures of lung metastases derived from intestinal tumors 
expressing activated MEK1 or MEK2.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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itored the expression of Bcl-2 anti-apoptotic and pro-
apoptotic family proteins. Constitutive activation of
MEK1 or MEK2 resulted in the up-regulation of the pro-
survival proteins Mcl-1, Bcl-2 and, to a lesser extent, Bcl-xL
in IEC-6 cells (Fig. 5B). Our results confirm and extend
previous observations [47,48] by demonstrating that both
MEK1 and MEK2 isoforms share the property to induce
the accumulation of Bcl-2 family pro-survival members.
Reciprocally, induction of the BH3-only pro-apoptotic
protein Bim was completely suppressed in cells expressing
MEK1DD or MEK2DD (Fig. 5C). This finding is consistent
with previous reports documenting the role of the ERK1/
2 MAP kinase pathway in promoting the degradation of
Bim [49,50]. MEK1 or MEK2 activation had no significant
effect on the expression of the pro-apoptotic proteins Bax
and Bak in these cells (data not shown).
Silencing of MEK2 expression markedly inhibits the 
proliferation of human colon cancer cells
The results presented above clearly demonstrate that con-
stitutive activation of either MEK isoform, MEK1 or
MEK2, is sufficient to fully transform intestinal epithelial
cells to the metastatic stage. We next wanted to determine
if human colon cancer cells depend on the activity of MEK
isoforms for cell proliferation. Several human colon carci-
noma cell lines display constitutive phosphorylation of
ERK1/ERK2 MAP kinases [20], likely resulting from acti-
vation of MEK1/MEK2. The HCT116 cell line, which rep-
resents one of the best studied model of colorectal cancer
cells, display constitutive activation of the two MEK iso-
forms (Fig. 6A). To assess the individual roles of MEK1
and MEK2, we expressed short-hairpin (sh) RNAs specifi-
cally targeting MEK1 or MEK2 gene in HCT116 cells using
VSV-pseudotyped lentiviral vectors. We tested the effect of
5 distinct shRNAs for MEK1 and 3 shRNAs for MEK2,
using as control a GFP-encoding vector. We selected the
two most efficient shRNAs to MEK1 and MEK2 genes
(Additional file 3). A non-silencing inactive MEK1 shRNA
was used as additional negative control in these experi-
ments. The efficiency of transduction estimated by GFP
immunofluorescence was over 90%, and therefore the
experiments were performed without cellular selection. As
shown by immunoblot analysis, lentivirus-mediated
delivery of MEK1 shRNAs resulted in complete silencing
of MEK1 expression with no effect on MEK2, whereas the
two MEK2 shRNAs markedly knocked-down MEK2
expression without affecting MEK1 isoform (Fig. 6B). We
then analyzed the functional consequence of MEK1 or
MEK2 silencing on the proliferation rate of the cells. Strik-
ingly, lowering of MEK2 expression with the two shRNAs
completely suppressed the proliferation of HCT116 cells,
whereas MEK1 shRNAs exerted a significant but much
weaker effect (Fig. 6B). The extent of inhibition observed
with MEK2 shRNAs was similar to that obtained by treat-
ing cells with the non-selective MEK1/2 inhibitor U0126.
Expression of proteases in IEC-6 cell populations transduced  with activated MEK isoforms Figure 4
Expression of proteases in IEC-6 cell populations 
transduced with activated MEK isoforms. (A) Expres-
sion of MMP-13 was analyzed by immunoblotting. Induction 
of MMP activity was analyzed by zymography on acrylamide 
gels co-polymerized with casein (MMP-3/10) or gelatin 
(MMP2 and MMP9) substrates. Photographs of the gels are 
shown. (B) Quantitative PCR analysis of urokinase receptor 
mRNA levels. Expression levels are expressed as fold-
increase relative to vector-infected cells.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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Constitutive activation of MEK1 or MEK2 confers intestinal epithelial cells resistance to anoikis Figure 5
Constitutive activation of MEK1 or MEK2 confers intestinal epithelial cells resistance to anoikis. (A) IEC-6 cell 
populations infected with vector alone or activated MEK1 or MEK2 were cultured in suspension on poly-HEMA-coated plates 
for the indicated times. Apoptosis was evaluated by TUNEL assay. (B and C) Expression of Bcl-2 anti-apoptotic (B) and pro-
apoptotic (C) family proteins was analyzed by immunoblotting in cell extracts from IEC-6 cell populations described in A. Total 
actin was used as loading control.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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Impact of MEK1 or MEK2 silencing on the proliferation of human colon carcinoma cell lines Figure 6
Impact of MEK1 or MEK2 silencing on the proliferation of human colon carcinoma cell lines. (A) Immunoblot 
analysis of MEK1, MEK2 and phospho-MEK1/2 expression in the human colon carcinoma cell lines HCT116, HT-29 and 
SW480, and in the breast adenocarcinoma line MDA-MB-231. Lysates were prepared from cells deprived of serum for 24 h (c), 
restimulated with serum for 5 min (+), or proliferating exponentially (exp). (B to D) HCT116 (B), SW480 (C) and HT-29 (D) 
cells were infected with MEK1 or MEK2 shRNA-encoding lentiviruses. A non-silencing inactive MEK1 shRNA (NS) was used as 
negative control. The cells were replated 72 h (day 0) after infection to monitor the expression of MEK1 and MEK2 and to 
measure the rate of cell proliferation. Expression of MEK isoforms was analyzed by immunoblotting at day (D) 1, 3 and 5 (left). 
Cell proliferation was measured each day using the MTT assay (right). For experiments with small-molecule MEK1/2 inhibitor, 
the cells were treated with 10 μM U0126 added at 48 h intervals.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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We also showed that silencing of MEK1 or MEK2 expres-
sion significantly reduces the extent of ERK1 and ERK2
activating phosphorylation (Fig. 7).
To verify whether this differential contribution of MEK
isoforms could be generalized to other colorectal cancer
cells, we examined the impact of MEK1 or MEK2 silencing
on the proliferation of two other human colon cancer cell
lines. We specifically chose the human colon carcinoma
cell lines SW480 (which harbors a KRAS mutation like
HCT116) and HT-29 (harboring a BRAF  mutation).
SW480 cells display a comparable expression pattern of
MEK1 and MEK2 proteins as HCT116 cells (Fig. 6A). Sim-
ilar to HCT116 cells, knock-down of MEK2 expression
dramatically suppressed the proliferation of SW480 cells,
whereas MEK1 silencing induced a significant but much
lower decrease of cell proliferation (Fig. 6C). Similar
results were obtained in HT-29 cells, except that the inhib-
itory effect of MEK1 shRNAs on proliferation was quanti-
tatively more important than on HCT116 and SW480
cells (Fig. 6D). This observation could be explained by the
much higher expression of MEK1 in the HT-29 cell line as
compared to HCT116 or SW480 cells (Fig. 6A), which
may have a more important contribution to total MEK1/2
signaling. However, the single inactivation of MEK2 was
still capable of abolishing the proliferation of HT-29 cells
even in the presence of high MEK1 levels. For all colorec-
tal cancer cell lines tested, the inhibition of proliferation
seen with MEK2 shRNAs was comparable to that achieved
with the MEK1/2 inhibitor U0126.
To further extend our investigation to non-colorectal car-
cinomas, we tested the effect of MEK1 and MEK2 shRNAs
on the human breast adenocarcinoma cell line MDA-MB-
231, which exhibit strong constitutive activation of
MEK1/MEK2 signaling (Fig. 6A). Interestingly, the MEK2
shRNA-06 completely inhibited the proliferation of MDA-
MB-231 cells to the same extent as the drug inhibitor
U0126 (Additional file 4). The other MEK2 shRNA-08
also markedly but not completely inhibited cell prolifera-
tion, consistent with its lower silencing activity in these
cells. Expression of MEK1 shRNAs suppressed cell prolif-
eration by approximately 50%.
Discussion
The ERK1/2 MAP kinase signaling pathway plays a central
role in cell proliferation control. Activation of ERK1/ERK2
is essential for G1 to S phase progression and is associated
with induction of cyclin Ds and inhibition of anti-prolif-
erative genes [51]. Studies in various experimental models
Silencing of MEK1 or MEK2 expression restrains activating phosphorylation of the MAP kinases ERK1/ERK2 Figure 7
Silencing of MEK1 or MEK2 expression restrains activating phosphorylation of the MAP kinases ERK1/ERK2. 
HCT116 cells were infected with lentiviruses encoding shRNAs to MEK1 or MEK2 gene. The expression of MEK1/MEK2, 
ERK1/ERK2 and phospho-ERK1/2 was measured by immunoblotting at day 1 as described in the legend of Figure 6. NS, non-
silencing inactive MEK1 shRNA.BMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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have also implicated the Raf-MEK1/2-ERK1/2 pathway in
the control of cell survival [52]. Consistent with a role in
cell cycle and survival signaling, there is growing evidence
that activation of the ERK1/2 pathway is involved in the
pathogenesis of human cancer (see Introduction). Specif-
ically, several observations point towards a role of this
pathway in colorectal cancer [26]. First, the EGF receptor,
a known activator of the ERK1/2 pathway, is expressed in
more than 70% of colorectal cancers [53]; treatment with
the EGF receptor monoclonal antibody cetuximab
improves overall survival in patients with colorectal can-
cer [54]. Second, KRAS and BRAF genes are mutated in
approximately 50% of colorectal cancers [3]. Third, acti-
vating phosphorylation of ERK1/ERK2 MAP kinases is fre-
quently observed in human colorectal cancer cell lines
and tumor specimens [20]. Finally, treatment with syn-
thetic MEK1/2 inhibitors markedly attenuates the prolif-
eration of colon carcinoma cells in vitro and in mouse
xenografts [20]. Despite such evidence, several important
questions about the contribution of the ERK1/2 MAP
kinase pathway to the initiation and progression of color-
ectal cancer remain unanswered.
In this study, we show that constitutive activation of
MEK1 or MEK2 isoform, as observed in 44% of colorectal
cancers, is sufficient to fully transform normal intestinal
epithelial cells and that maintenance of MEK1/MEK2
activity is necessary to sustain the proliferation of human
colon carcinoma cells. This is the first report to compare
the ability of the two MEK isoforms to transform epithe-
lial cells. Previous studies have shown that activated
MEK1 can transform immortalized fibroblasts [10,11] as
well as epithelial cells [13,55,56]. Intriguingly, it was also
reported that activated Ras, but not Raf-1, causes transfor-
mation of mammary and intestinal epithelial cells, sug-
gesting that signaling events other than activation of
MEK1/2 are essential for oncogenic Ras transformation
[57]. Here, we clearly establish that expression of activated
MEK1 is sufficient to morphologically transform intesti-
nal epithelial cells, accelerate cell proliferation, and
induce the rapid formation of aggressive tumors after
orthotopic transplantation. Moreover, we reveal for the
first time that the MEK2 isoform has similar transforming
properties and is able to induce the formation of tumors
in mice. This knowledge is important since both MEK1
and MEK2 are expressed in intestinal epithelial cells and
immunohistochemistry analysis with phospho-specific
MEK1/2 antibodies does not allow to discriminate
between the two isoforms. Immunoblot analysis under
electrophoresis conditions that partially resolve the two
isoforms indicates that both MEK1 and MEK2 are phos-
phorylated in human colon carcinoma cell lines (Fig. 6A).
The signaling pathways underlying the progression of
colorectal cancer to advanced metastatic disease are
poorly understood. The development of metastatic
tumors is a complex process that consists of a series of cel-
lular events that move neoplastic cells from the primary
tumor to a distant location [58]. Cancer cells must detach
from the tumor and invade the surrounding tissue,
degrade the basement membrane, disseminate and sur-
vive into the circulation systems, extravasate into a new
tissue, and colonize their new microenvironment. During
this process, tumor cells have to face different kinds of
stress. Recent studies have suggested that Ras signaling
may contribute to metastasis formation in colorectal can-
cer [59], although the downstream effector pathways
involved remain unclear. Here, we show that expression
of activated MEK1 or MEK2 not only induces the forma-
tion of intestinal tumors but also promotes later stages of
tumor progression and metastasis to distant organs. To
address the impact of MEK1/MEK2 signaling on tumor
progression, we have used an orthotopic implantation
model that provides a more accurate picture of the meta-
static process [60]. A large proportion of the tumors
expressing activated MEK1 or MEK2 metastasized to the
liver and lung, the two most common sites of human
colorectal cancer metastasis, thereby validating the patho-
logical relevance of our model. The ability of activated
MEK1- or MEK2-expressing tumor cells to colonize dis-
tant organs was associated with increased invasiveness,
secretion of matrix proteases and resistance to anoikis.
Interestingly, an early study reported that the enzymatic
activity of ERK1/ERK2 is markedly up-regulated during
late progression of carcinogen-induced colon carcinomas
[61]. Together, these observations strengthen the idea that
ERK1/2 MAP kinase signaling plays a critical role in color-
ectal cancer progression [26].
An important finding of this study is the observation that
MEK1 and MEK2 may contribute differentially to the
pathogenesis of colorectal cancer. While activation of a
single MEK isoform was shown to be sufficient for full
neoplastic transformation of intestinal epithelial cells, we
observed that MEK2DD-expressing cells display a slightly
more transformed morphology and are more invasive
than cells expressing MEK1DD in vitro. This was associ-
ated with a more prominent down-regulation of E-cad-
herin and a stronger up-regulation of MMPs and
urokinase receptor. The physiopathological relevance of
these in vitro properties is unclear, however, since no dif-
ference in the metastatic behavior of the cells was
observed upon orthotopic transplantation in mice. The
simplest explanation for this apparent discrepancy is that
in vitro invasiveness assays do not replicate the complex
and multistage process of tumor metastasis in vivo. Most
importantly, we found that silencing of MEK2 expression
(even if not total) completely suppressed the proliferation
of human colon carcinoma cell lines, whereas complete
knock-down of MEK1 had a much weaker effect. TheBMC Cancer 2008, 8:337 http://www.biomedcentral.com/1471-2407/8/337
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extent of inhibition observed with MEK2 shRNAs was
comparable to that obtained with the non-selective
MEK1/2 inhibitor U0126. This differential impact of
MEK1 and MEK2 on cell proliferation was observed in
three different colon carcinoma cell lines (bearing activat-
ing mutations in either KRAS or BRAF), as well as in the
breast adenocarcinoma cell line MDA-MB-231. The
molecular basis for these differences remains to be estab-
lished. One possibility is that MEK2 is expressed at higher
levels than MEK1 in colon cancer cells. However, immu-
noblot analysis clearly indicates that HT-29 cells express
more phosphorylated MEK1 (lower band in upper panel
of Fig. 6A) than MEK2, arguing that quantitative differ-
ence in expression levels does not explain everything. Our
results rather suggest that the two MEK isoforms may be
differentially regulated or may target distinct effector
pathways in certain cellular and/or genetic contexts.
Conclusion
In conclusion, we demonstrate that the two MAP kinase
kinase isoforms MEK1 and MEK2 have similar transform-
ing properties and that activation of either isoform is suf-
ficient for full transformation of intestinal epithelial cells
up to the metastatic stage. Interestingly, our results indi-
cate that MEK2 plays a more important role than MEK1 in
sustaining the proliferation of human colorectal cancer
cells, suggesting that the two MEK isoforms may contrib-
ute differentially to tumor pathogenesis in certain con-
texts.
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